Total mortality by transferrin saturation levels: Two general population studies and a metaanalysis

Clinical Chemistry

Volumn 57, Issue 3, 2011, Pages 459-466

  Ellervik, Christina ^a,b,c   Tybjærg Hansen, Anne ^a,c,d,e   Nordestgaard, Børge G ^a,c,e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NAESTVED HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; TRANSFERRIN;

ADULT; AGED; ARTICLE; CHEMICAL PARAMETERS; DENMARK; FEMALE; FOLLOW UP; HEMOCHROMATOSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TRANSFERRIN SATURATION;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; FEMALE; FOLLOW-UP STUDIES; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POPULATION SURVEILLANCE; TRANSFERRIN;

EID: 79952215851     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.156802     Document Type: Article

References (41)

1. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-53.
2. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
3. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-72.
4. Milman N, Pedersen P, Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001;80:737-44.
5. Crooks CJ, West J, Solaymani-Dodaran M, Card TR. The epidemiology of haemochromatosis: a population-based study. Aliment Pharmacol Ther 2009;29:183-92.
6. Mainous AG III, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. Ann Fam Med 2004;2:133-8. (Pubitemid 39329081)
7. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
8. Orsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 2007;204:1295-301. (Pubitemid 46919867)
9. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007;25:57-63. (Pubitemid 350003051)
10. Cartwright GE, Edwards CQ, Kravitz K, Skolnick M, Amos DB, Johnson A, Buskjaer L. Hereditary hemochromatosis: phenotypic expression of the disease. N Engl J Med 1979;301:175-9. (Pubitemid 10249620)
11. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-62.
12. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24. (Pubitemid 29407371)
13. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community: a 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002;23:620-6. (Pubitemid 35204246)
14. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-9. (Pubitemid 38685730)
15. Schnohr P, Lange P, Scharling H, Jensen JS. Long-term physical activity in leisure time and mortality from coronary heart disease, stroke, respiratory diseases, and cancer. The Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 2006;13:173-9. (Pubitemid 44097720)
16. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993. 383 p.
17. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201. (Pubitemid 38249333)
18. Reunanen A, Takkunen H, Knekt P, Seppanen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995;238:223-30.
19. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. Am J Epidemiol 1996;144:59-68. (Pubitemid 26225288)
20. van Asperen I, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665-70.
21. Wells BJ, Mainous AG III, King DE, Gill JM, Carek PJ, Geesey ME. The combined effect of transferrin saturation and low density lipoprotein on mortality. Fam Med 2004;36:324-9. (Pubitemid 39030324)
22. Egger M, Smith GD, Altman DG. Systematic reviews in health care. London: BMJ Books; 2003. 497 p.
23. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206.
24. Ellervik C, Tybjaerg-Hansen A, Appleyard M, Ibsen H, Nordestgaard BG. Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med 2010;268:252-64.
25. Cheng WE, Shih CM, Hang LW, Wu KY, Yang HL, Hsu WH, Hsia TC. Urinary biomarker of oxidative stress correlating with outcome in critically septic patients. Intensive Care Med 2007;33:1187-90.
26. Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear 8-hydroxy-2′-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncol Rep 2010;23:329-35.
27. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-73. (Pubitemid 34162750)
28. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a European experience. Br J Haematol 2000;108:31-9.
29. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976;45:611-23.
30. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62. (Pubitemid 16217048)
31. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-9.
32. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-9. (Pubitemid 38451659)
33. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 2006;1067:10-21. (Pubitemid 43806304)
34. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.
35. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
36. Buijsse B, Feskens EJ, Moschandreas J, Jansen EH, Jacobs DR Jr, Kafatos A, et al. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil 2007;14:495-500. (Pubitemid 47229728)
37. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overloadrelated disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
38. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8. (Pubitemid 34113819)
39. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-23. (Pubitemid 46780566)
40. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008;111:3373-6.
41. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.